What question did this study set out to answer?

To investigate how kidney histology changes in patients with IgA nephropathy treated with sibeprelimab.

March 28, 2026Open Access

WCN26-5800 VISOR: AN ONGOING REPEAT-BIOPSY CLINICAL TRIAL ASSESSING CHANGES IN KIDNEY HISTOLOGY IN PEOPLE WITH IgA NEPHROPATHY TREATED WITH SIBEPRENLIMAB

Key Points

To investigate how kidney histology changes in patients with IgA nephropathy treated with sibeprelimab.
Ongoing repeat-biopsy clinical trial
Compared early and late lupus nephritis groups
Assessed differences in immunosuppressive regimens and outcomes
Class IV nephritis was common in both early and late groups.
No significant difference in the incidence of ESRD between groups (20.4% vs. 31.7%).
Mean time to remission was similar for both groups (approx. 8.6 months).

Abstract

compared to late LN (12.5% ,p=0.04).Class IV nephritis predominated in both groups (early: 69.3%; delayed: 61.0%; p=0.44).Immunosuppressive regimens were comparable between the groups, though the use of cyclophosphamide was higher in early nephritis .There was no significant difference in the incidence of ESRD (20.4% in early vs. 31.7% in late, p=0.23) or mortality (12.2% vs. 19.5%,p=0.38).The mean time to remission was also similar (8.59 vs. 8.63 months; p=0.98).Early Late P value Median age at LN diagnosis 23.5 29 0.08

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper